Portal Vein and Hepatic Vein Embolization for Liver Cancer
The Dragon PLC Trial (DRAGON-PLC)
Recruiting
N/A
Interventional Study
Primary Liver Cancer
Hepatocellular Carcinoma (HCC)
Cholangiocarcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 358 (estimated)
- Sponsor
- Maastricht University · Other
Who this trial is looking for
This trial is looking for patients with certain types of liver cancer who may need a specific procedure. Participants will receive treatment and undergo regular checks on their liver health for up to 5 years.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with liver cancer.
- I need portal vein embolization because my liver function is not adequate.
- I am at least 18 years old.
- I can understand the trial and give my consent.
You may not be able to join if
- I have liver cirrhosis with a Child-Pugh score of B or C.
- I have portal hypertension.
- I have cholangitis.
- I am pregnant.
- I am a premenopausal female unable to commit to contraception.
- I have other liver cancers besides the specified types.
- My anatomy makes the procedures impossible.
- I have extrahepatic metastatic disease that can't be treated.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma.
The main questions th…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* PLC diagnosis, specifically iCCC, pCCC, and HCC;
* Requiring PVE due to an FLR volume is \<30% in normally functioning livers, \<40% in livers with potentially impaired function e.g. resulting from prior systemic therapy induction or bile duct colonization / transpapillary bil…
Contacts